FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Emcure Pharma IPO and Sanstar IPO.
Emcure Pharma IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Sanstar IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.
Emcure Pharma IPO | Sanstar IPO | |
---|---|---|
Logo | ||
Issue Category | Mainline | Mainline |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | BSE, NSE | BSE, NSE |
Lead Managers | Kotak Mahindra Capital Company Limited Axis Capital Limited J.P. Morgan India Private Limited Jefferies India Private Limited |
Pantomath Capital Advisors Pvt Ltd |
Registrar | Link Intime India Private Ltd | Link Intime India Private Ltd |
Market Maker | ||
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | Anchor Investor | Anchor Investor |
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Emcure Pharma IPO is up to ₹1,952.03 Cr whereas the issue size of the Sanstar IPO is up to ₹510.15 Cr. The final issue price of Emcure Pharma IPO is ₹1,008.00 per share and of Sanstar IPO is ₹95.00 per share.
Emcure Pharma IPO | Sanstar IPO | |
---|---|---|
Face Value | ₹10 per share | ₹2 per share |
Issue Price (Lower) | ₹960.00 per share | ₹90.00 per share |
Issue Price (Upper) | ₹1,008.00 per share | ₹95.00 per share |
Issue Price (Final) | ₹1,008.00 per share | ₹95.00 per share |
Discount (Retail) | ||
Discount (Employee) | ₹90.00 per share | |
Market Lot Size | 14 shares | 150 shares |
Fresh Issue Size | 79,36,507 shares | 4,18,00,000 shares |
Fresh Issue Size (Amount) | up to ₹800.00 Cr | up to ₹397.10 Cr |
OFS Issue Size | 1,14,28,839 shares | 1,19,00,000 shares |
OFS Issue Size (Amount) | up to ₹1,152.03 Cr | up to ₹113.05 Cr |
Issue Size Total | 1,93,65,346 shares | 5,37,00,000 shares |
Issue Size Total (Amount) | up to ₹1,952.03 Cr | up to ₹510.15 Cr |
Emcure Pharma IPO opens on Jul 03, 2024, while Sanstar IPO opens on Jul 19, 2024. The closing date of Emcure Pharma IPO and Sanstar IPO is Jul 05, 2024, and Jul 23, 2024, respectively.
Emcure Pharma IPO | Sanstar IPO | |
---|---|---|
Anchor Bid Date | Jul 02, 2024 | Jul 18, 2024 |
Issue Open | Jul 03, 2024 | Jul 19, 2024 |
Issue Close | Jul 05, 2024 | Jul 23, 2024 |
Basis Of Allotment (Tentative) | Jul 08, 2024 | Jul 24, 2024 |
Initiation of Refunds (Tentative) | Jul 09, 2024 | Jul 25, 2024 |
Credit of Share (Tentative) | Jul 09, 2024 | Jul 25, 2024 |
Listing date (Tentative) | Jul 10, 2024 | Jul 26, 2024 |
Anchor Lockin End date 1 | Aug 07, 2024 | Aug 23, 2024 |
Anchor Lockin End date 2 | Oct 06, 2024 | Oct 22, 2024 |
Emcure Pharma IPO P/E ratio is 34.55, as compared to Sanstar IPO P/E ratio of 19.98.
Emcure Pharma IPO | Sanstar IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial | Emcure Pharmaceuticals Limited Financial Information (Restated Consolidated)Emcure Pharmaceuticals Limited's revenue increased by 11.33% and profit after tax (PAT) dropped by -6.1% between the financial year ending with March 31, 2024 and March 31, 2023.
|
Sanstar Limited Financial Information (Restated Consolidated)Sanstar Limited's revenue decreased by -10.58% and profit after tax (PAT) rose by 59.71% between the financial year ending with March 31, 2024 and March 31, 2023.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 98.90% | 99.77% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 78.24% | 70.37% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | 34.55 | 19.98 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ₹19029.89 Cr. | ₹1731.32 Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROE | 16.90%% | 30.92%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ROCE | 19.37%% | 24.43%% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | 0.67 | 0.5 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EPS | ₹29.17 | ₹4.75 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
RoNW | 16.87%% | 30.92%% |
In the Emcure Pharma IPO retail investors (RII) are offered 67,43,160 shares while in Sanstar IPO retail investors are offered 67,43,160 shares. Qualified institutional buyers (QIB) are offered 38,53,234 shares in Emcure Pharma IPO and 1,07,40,000 shares in Sanstar IPO.
Emcure Pharma IPO | Sanstar IPO | |
---|---|---|
Anchor Investor Reserveration | 57,79,850 shares | 1,61,10,000 shares |
Market Maker Reserveration | ||
QIB | 38,53,234 shares | 1,07,40,000 shares |
NII | 28,89,926 shares | 80,55,000 shares |
RII | 67,43,160 shares | 1,87,95,000 shares |
Employee | 1,08,900 shares | 0 shares |
Others | ||
Total | 1,37,03,538 shares | 3,75,90,000 shares |
Emcure Pharma IPO subscribed 67.87x in total, whereas Sanstar IPO subscribed 82.99x.
Emcure Pharma IPO | Sanstar IPO | |
---|---|---|
QIB (times) | 191.24x | 145.68x |
NII (times) | 49.32x | 136.49x |
Big NII (times) | 54.90x | 149.44x |
Small NII (times) | 38.16x | 110.61x |
RII (times) | 7.36x | 24.23x |
Employee (times) | 8.81x | |
Other (times) | ||
Total (times) | 67.87x | 82.99x |
Add a public comment...
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|